COMP <GO>
MIRA vs CRVO // EV/EBITDA & P/E VALUATION
MIRA Pharmaceuticals Inc. (NASDAQ) VS. CervoMed Inc. (NASDAQ) • 15-METRIC TALLY: MIRA 1
— CRVO 1
■ METRIC PARITY
LAST: $0.54 (-2.06%) • MKT CAP: $23.0M
valuation
—
LAST: $1.64 (+2.50%) • MKT CAP: $24.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MIRA VS. CRVO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MIRA | CRVO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -19.41% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -58.90% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.7 | 28.2 | +7.50 | MIRA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.0M | $24.2M | -$1.1M | CRVO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MIRA REV | CRVO REV | MIRA GROSS % | CRVO GROSS % | MIRA FCF | CRVO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.7M | $4.0M | — | — | -$4.7M | -$23.4M |
| FY 2024 | $1.2M | $9.7M | — | — | -$5.6M | -$16.5M |
| FY 2023 | $53.9M | $7.1M | — | — | -$4.5M | -$7.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MIRA // BETA —
CRVO // BETA —